Resources
BOSTON, April 30, 2019 — OM1, a leading health outcomes, data and technology company today announced that its rheumatology registries, which track hundreds of thousands of patients longitudinally throughout the United States, are now available for direct licensing as well as studies and advanced analytics. The registries include: Rheumatoid Arthritis Systemic Lupus Erythematosus Sjögrens Giant[…]
Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence Richard E. Gliklich MD, Michelle B. Leavy, MPH Sage Journals, First Published March 27, 2019 The use of real-world data and real-world evidence to inform health care decisions is increasing. Yet, the variable quality of these data and[…]
Read the decision memo: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=292
BOSTON, January 16, 2019 — OM1, a leading health outcomes, registries and technology company creating solutions to better understand, compare, and predict patient outcomes, today announced that its Rheumatoid Arthritis (RA) registry has reached more than 100,000 patients with deep clinical data and is available for licensing, studies and advanced analytics. RA is a chronic autoimmune[…]
December 18, 2018 – PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named OM1 as one of the most innovative Services of 2018. Founded in 2015, OM1 is a health outcomes and technology company leveraging big clinical data, standardized outcome measurement, and artificial intelligence[…]
